ONTX
$0.26
Onconova Therapeutic
($.01)
(2.76%)
ONTX
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.02)
Revenue:  $4.10 Mil
Tuesday
Nov 10
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ONTX reports earnings?
Beat
Meet
Miss

Where is ONTX's stock price going from here?
Up
Flat
Down
Stock chart of ONTX
Analysts
Summary of analysts' recommendations for ONTX
Score
Grade
Pivots
Resistance
$0.28
$0.27
$0.27

$0.26

Support
$0.26
$0.25
$0.25
Tweet
Growth
Description
Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx Pharmaceutical